PLYMOUTH MEETING, Pa., Sept. 17, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conference:World Congress of ElectroporationOral Presentation by Trevor Smith, VP of Preclinical R&D at INOVIOAbstract Title: Development of in vivo-launched synthetic DNA-encoded antibodies employin ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President & Chief Executive Officer Steve Egge - Chief Commercial Officer Michael Sumner - Chief Medical Officer Peter Kies - Chief Financial Officer Conference Call Participants Anish Nikhanj - RBC Capital Markets Roy Buchanan - Citizens JMP Jay Olson - Oppenheimer Sudan Loganathan - Stephens Yi Chen - H.C. Wainwright Operato ...

财务状况 - 公司现金及现金等价物为3,439.24万美元，较上年同期减少[1] - 公司短期投资为7,602.91万美元，较上年同期减少[1] - 公司预计现金储备可维持至2025年第三季度[11] - 公司通过股票发行筹集了3320万美元的净资金,以加强资产负债表[8] 经营情况 - 第二季度研发费用为2,309.10万美元,较上年同期略有下降[9] - 第二季度总运营费用为3,330万美元,较上年同期下降[9] - 公司研发费用为2,309.10万美元，较上年同期减少[2] - 公司一般及行政费用为1,020.67万美元，较上年同期减少[2] - 公司利息收入为130.74万美元，较上年同期减少[2] - 公司投资联营公司的亏损为33.43万美元[2] - 公司可供出售权益证券的未实现亏损为2.08万美元[2] - 公司净亏损为3,223.71万美元，较上年同期减少[2] - 公司每股基本及稀释亏损为1.19美元，较上年同期减少[2] - 公司加权平均股数为2,719.78万股，较上年同期增加[2] 产品管线进展 - 公司正在推进INO-3107的生物制药许可申请(BLA)准备工作,但由于制造单次使用一次性给药装置组件出现问题,预计将延迟至2025年中期提交BLA[3] - 公司已获得INO-3107在英国的创新药物认证,以及欧洲药品管理局高级治疗药物产品(ATMP)认证[5] - 公司提交了INO-3112用于治疗口咽鳞状细胞癌(OPSCC)的III期临床试验方案,并获得FDA的积极反馈[6] - 公司计划在第三季度向FDA重新提交INO-4201作为Ebola疫苗的异源性增强剂的II/III期临床试验方案[7] - 公司任命Steve Egge为首席商务官,负责INO-3107的商业化策略和运营[8]

PLYMOUTH MEETING, Pa., Aug. 8, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter of 2024 and provided an update on recent company developments."We continue to make progress with our lead candidate, INO-3107, which has the potential to significantly improve the lives of patients with RR ...

临床试验进展 - 公司正在开发INO-3107用于治疗复发性呼吸道乳头状瘤(RRP)，81.3%的患者在治疗后一年内手术次数减少[89] - INO-3107在临床试验中产生了强大的免疫反应，激活了CD4和CD8 T细胞[89] - 公司计划在2025年中期提交INO-3107的生物制品许可申请(BLA)[89] - 公司正在开发INO-3112用于治疗HPV16/18阳性的口咽鳞状细胞癌(OPSCC)[89] - 公司正在开发INO-5401用于治疗恶性胶质瘤(GBM)[89] 财务状况 - 公司2024年上半年的总收入为10.1万美元[92] - 公司2024年上半年的研发费用为2309.1万美元[92] - 公司2023年6月30日的累计亏损为17亿美元[90] - 公司预计未来将继续产生大额的经营亏损[90] - 公司预计现金储备可维持至2025年第三季度[101] - 2024年4月完成了3.32亿美元的增发[100] 费用分析 - 研发费用同比下降的主要原因包括:停止INO4800项目导致相关制药和临床试验费用减少7.4百万美元[95]、员工和顾问薪酬(含股票激励)减少7.2百万美元[95]、停止其他COVID-19研究相关的制药和工程服务费用减少3.2百万美元[95]、其他项目的制药费用减少4.7百万美元[95][1] - 一般及行政费用同比下降,主要是员工薪酬(含股票激励)减少3.9百万美元[96]、法律费用减少2.3百万美元[96][2] - 股票激励费用同比下降,主要是2024年授予的股票平均授予日公允价值较低[96][3] - 利息收入同比下降,主要是短期投资余额减少[96][4] - 利息费用同比下降,主要是可转换票据已于2024年3月全额偿还[96][5] - 投资联营公司公允价值变动损失为460,000美元[96][6] - 可供出售股权证券公允价值变动收益为480,000美元[96][7]

Data reviewed complies with standards that would be used to evaluate an EU Marketing Authorization ApplicationPLYMOUTH MEETING, Pa., July 25, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the European Medicines Agency's Committee for Advanced Therapies (CAT) has certified the quality and non-clinical data for INO-3107, ...

Inovio Pharmaceuticals (INO) jumped 19% on Jul 11, after it announced that its lead DNA medicine candidate, INO-3107, has received the Innovation Passport designation under the United Kingdom's Innovative Licensing and Access Pathway (ILAP). This designation was granted by the ILAP Steering Group for the treatment of recurrent respiratory papillomatosis (RRP).RRP is a rare degenerative disease that causes small growths (papillomas) in the respiratory tract. Generally, non-cancerous papillomas can cause seve ...

Inovio Pharmaceuticals (INO) shares rallied 19% in the last trading session to close at $11.04. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 2.1% loss over the past four weeks.The sudden soaring of the stock price was observed after Inovio announced that its lead DNA medicine candidate, INO-3107, has received the Innovation Passport designation under the United Kingdom's Innovative Licensing and Access Pat ...

Award recognizes the potential for INO-3107 to be the first therapeutic option in the United Kingdom for patients suffering from Recurrent Respiratory Papillomatosis (RRP)PLYMOUTH MEETING, Pa., July 11, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its lead DNA medicine candidate, INO-3107, has been designated an innova ...

Mr. Egge brings over 25 years of biopharmaceutical experience building commercial organizations and successfully launching novel therapeutic products INOVIO poised to become a commercial-stage company with plans to submit a Biologics License Application for INO-3107 in second half of 2024 under U.S. Food and Drug Administration's Accelerated Approval Pathway PLYMOUTH MEETING, Pa., July 2, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicine ...